7 companies in Longevity.
Longeveron
Longevity · Regeneration · Cell therapy for ageing-related and other conditions
Latest (Oct 26, 2026): Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Open profile →BioAge Labs
Longevity · Drug development informed by the biology of ageing
Latest (Aug 5, 2026): BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Open profile →Cambrian Bio
Longevity · A group of companies developing drugs aimed at ageing biology
Latest (Jul 15, 2026): Cambrian Bio reports $123.8 million of equity sold in a private offering
Open profile →Life Biosciences
Longevity · Partial epigenetic reprogramming
Latest (Apr 24, 2026): Life Biosciences reports $31 million of equity sold in a private offering
Open profile →NewLimit
Longevity · Epigenetic reprogramming
Latest (May 15, 2025): NewLimit reports $129.8 million of equity sold in a private offering
Open profile →Rejuvenate Bio
Longevity · Gene & cell engineering · Gene therapy for ageing-related disease
Latest (Jun 18, 2026): Rejuvenate Bio reports $19.5 million of equity sold in a private offering
Open profile →Loyal (Cellular Longevity)
Longevity · Lifespan-extension drugs for dogs
No developments in the current window yet.
Open profile →Coverage is not an offer to invest. Private ownership does not imply available shares. Sector labels are Sapien Frontier’s own coverage classification, not company claims.
Missing a company? Request future coverage. We add a company when its filings, offering notices or awards can be followed reliably. See what we cover and how often.